Tenecteplase for Acute Ischemic Stroke Treatment

Abstract

The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis with fewer hemorrhagic complications. Also, easier bolus-only administration makes TNK a very practical rt-PA alternative. In several clinical trials, TNK has shown similar efficacy and safety to rt-PA, and the potential to be at least noninferior to rt-PA in some settings. TNK may be superior to rt-PA for reperfusing large vessel occlusions in patients with salvageable penumbra, although this has not yet translated to improved clinical outcomes. Further phase 3 studies are in progress comparing rt-PA with TNK for acute ischemic stroke during the first 4.5 hours. Studies are also in progress to evaluate the use of TNK for extended applications, such as wake-up stroke.

Keywords

stroke - treatment - tenecteplase - alteplase - recombinant tissue plasminogen activator - intravenous thrombolysis

Publication History

Article published online:
20 January 2021

• References

• 1 The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
• 2 Hacke W, Kaste M, Bluhmki E. et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 (13) 1317-1329
• 3 Del Zoppo GJ, Saver JL, Jauch EC, Adams Jr HP. American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40 (08) 2945-2948 Erratum in: Stroke 2010;41:e562
• 4 Thomalla G, Simonsen CZ, Boutitie F. et al; WAKE-UP Investigators. WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med 2018; 379 (07) 611-622
• 5 Ma H, Campbell BCV, Parsons MW. et al; EXTEND Investigators. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med 2019; 380 (19) 1795-1803
• 6 Campbell BCV, Ma H, Ringleb PA. et al; EXTEND, ECASS-4, and EPITHET Investigators. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. Lancet 2019; 394 (10193): 139-147
• 7 Saver JL, Goyal M, Bonafe A. et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015; 372 (24) 2285-2295
• 8 Berkhemer OA, Fransen PS, Beumer D. et al. MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11–20 Erratum in. N Engl J Med 2015; 372: 394
• 9 Goyal M, Demchuk AM, Menon BK. et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015; 372 (11) 1019-1030
• 10 Campbell BC, Mitchell PJ, Kleinig TJ. et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015; 372 (11) 1009-1018
• 11 Jovin TG, Chamorro A, Cobo E. et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015; 372 (24) 2296-2306
• 12 Bracard S, Ducrocq X, Mas JL. et al; THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016; 15 (11) 1138-1147 erratum in: Lancet Neurol 2016;15:1203
• 13 Mocco J, Zaidat OO, von Kummer R. et al; THERAPY Trial Investigators*. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke 2016; 47 (09) 2331-2338
• 14 Heiferman DM, Li DD, Pecoraro NC, Smolenski AM, Tsimpas A, Ashley Jr WW. Intra-arterial alteplase thrombolysis during mechanical thrombectomy for acute ischemic stroke. J Stroke Cerebrovasc Dis 2017; 26 (12) 3004-3008
• 15 Nogueira RG, Jadhav AP, Haussen DC. et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378 (01) 11-21
• 16 Albers GW, Marks MP, Kemp S. et al; DEFUSE 3 Investigators. DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378 (08) 708-718
• 17 Campbell BCV, Mitchell PJ, Churilov L. et al; EXTEND-IA TNK Investigators. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018; 378 (17) 1573-1582
• 18 Wei D, Oxley TJ, Nistal DA. et al. Mobile interventional stroke teams lead to faster treatment times for thrombectomy in large vessel occlusion. Stroke 2017; 48 (12) 3295-3300
• 19 Menon BK, Al-Ajlan FS, Najm M. et al; INTERRSeCT Study Investigators. Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke. JAMA 2018; 320 (10) 1017-1026
• 20 Bhatia R, Hill MD, Shobha N. et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke 2010; 41 (10) 2254-2258
• 21 Emberson J, Lees KR, Lyden P. et al; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384 (9958): 1929-1935
• 22 Yaghi S, Willey JZ, Cucchiara B. et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for health care professionals from the American Heart Association/American Stroke Association. Stroke 2017; 48 (12) e343-e361
• 23 Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis 2012; 34 (02) 106-114
• 24 Cornu C, Boutitie F, Candelise L. et al. Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. Stroke 2000; 31 (07) 1555-1560
• 25 Hacke W, Furlan AJ, Al-Rawi Y. et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8 (02) 141-150
• 26 Albers GW, von Kummer R, Truelsen T. et al; DIAS-3 Investigators. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015; 14 (06) 575-584
• 27 Chester KW, Corrigan M, Schoeffler JM. et al. Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase. Expert Opin Drug Saf 2019; 18 (02) 87-96
• 28 Keyt BA, Paoni NF, Refino CJ. et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91 (09) 3670-3674
• 29 Nelson A, Kelly G, Byyny R, Dionne C, Preslaski C, Kaucher K. Tenecteplase utility in acute ischemic stroke patients: a clinical review of current evidence. Am J Emerg Med 2019; 37 (02) 344-348
• 30 Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet 2002; 41 (15) 1229-1245
• 31 Van De Werf F, Adgey J, Ardissino D. et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354 (9180): 716-722
• 32 Cannon CP, Gibson CM, McCabe CH. et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998; 98 (25) 2805-2814
• 33 Coutts SB, Berge E, Campbell BCV, Muir KW, Parsons MW. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke 2018; 13 (09) 885-892
• 34 Thomas GR, Thibodeaux H, Errett CJ. et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25 (10) 2072-2078 , discussion 2078–2079
• 35 Benedict CR, Refino CJ, Keyt BA. et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92 (10) 3032-3040
• 36 Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32 (03) 748-752
• 37 Logallo N, Novotny V, Assmus J. et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16 (10) 781-788
• 38 Haley Jr EC, Lyden PD, Johnston KC, Hemmen TM. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36 (03) 607-612
• 39 Haley Jr EC, Thompson JL, Grotta JC. et al; Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; 41 (04) 707-711
• 40 Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol 2014; 261 (06) 1069-1072
• 41 Parsons MW, Miteff F, Bateman GA. et al. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72 (10) 915-921
• 42 Parsons M, Spratt N, Bivard A. et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012; 366 (12) 1099-1107
• 43 Huang X, Cheripelli BK, Lloyd SM. et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 2015; 14 (04) 368-376
• 44 Schwamm LH. Breaking up is hard to do: tenecteplase in acute stroke. Lancet Neurol 2015; 14 (04) 343-345
• 45 Bivard A, Huang X, Levi CR. et al. Tenecteplase in ischemic stroke offers improved recanalization: analysis of 2 trials. Neurology 2017; 89 (01) 62-67
• 46 Bivard A, Huang X, McElduff P. et al. Impact of computed tomography perfusion imaging on the response to tenecteplase in ischemic stroke: analysis of 2 randomized controlled trials. Circulation 2017; 135 (05) 440-448
• 47 Smadja D, Chausson N, Joux J. et al. A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tPA-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients. Stroke 2011; 42 (06) 1644-1647
• 48 Molina CA. Reperfusion therapies for acute ischemic stroke: current pharmacological and mechanical approaches. Stroke 2011; 42 (1, Suppl): S16-S19
• 49 Georgiadis AL, Memon MZ, Shah QA. et al. Intra-arterial tenecteplase for treatment of acute ischemic stroke: feasibility and comparative outcomes. J Neuroimaging 2012; 22 (03) 249-254
• 50 Coutts SB, Dubuc V, Mandzia J. et al; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke 2015; 46 (03) 769-774
• 51 Kate M, Wannamaker R, Kamble H. et al. Penumbral imaging-based thrombolysis with tenecteplase is feasible up to 24 hours after symptom onset. J Stroke 2018; 20 (03) 415
• 52 Ramakrishnan TCR, Kumaravelu S, Narayan SK. et al; Tenecteplase in Stroke Investigators. Efficacy and safety of intravenous tenecteplase bolus in acute ischemic stroke: results of two open-label, multicenter trials. Am J Cardiovasc Drugs 2018; 18 (05) 387-395
• 53 Owais M, Panwar A, Valupadas C, Veeramalla M. Acute ischemic stroke thrombolysis with tenecteplase: an institutional experience from South India. Ann Afr Med 2018; 17 (02) 90-93
• 54 Seners P, Caroff J, Chausson N. et al; PREDICT-RECANAL collaborators. Recanalization before thrombectomy in tenecteplase vs. alteplase-treated drip-and-ship patients. J Stroke 2019; 21 (01) 105-107
• 55 Huang X, MacIsaac R, Thompson JL. et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke 2016; 11 (05) 534-543
• 56 Zang Y, Hou J, Wang LY. Therapeutic effect of tenecteplase on treatment of cerebral arterial thrombosis: a meta-analysis. Eur Rev Med Pharmacol Sci 2016; 20 (20) 4369-4379
• 57 Kheiri B, Osman M, Abdalla A. et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis 2018; 46 (04) 440-450
• 58 Powers WJ, Rabinstein AA, Ackerson T. et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49 (03) e46-e110